Company Overview and News

 
Is General Finance (GFN) Outperforming Other Business Services Stocks This Year?

20h zacks
Investors focused on the Business Services space have likely heard of General Finance (GFN - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of GFN and the rest of the Business Services group's stocks.
GFN GFNCP GFDV GFNSL

 
The Motor & General Finance Limited - Updates

20h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GFN GFNCP GFDV GFNSL

 
General Finance Corporation Declares Dividend of $2.30 Per Share on Its 9.00% Series C Cumulative Redeemable Perpetual Preferred Stock

2018-10-12 globenewswire
PASADENA, Calif., Oct. 12, 2018 (GLOBE NEWSWIRE) -- General Finance Corporation (NASDAQ:GFN), a leading specialty rental services company offering portable storage, modular space and liquid containment solutions (the “Company”), announced today that in accordance with the terms of its 9.00% Series C Cumulative Redeemable Perpetual Preferred Stock (NASDAQ:GFNCP) (the “Series C Preferred Stock”), the Board of Directors has declared a cash dividend of $2.
GFN GFNCP GFDV GFNSL

 
The Motor & General Finance Limited - Trading Window

2018-10-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GFN GFNCP GFDV GFNSL

22
Zacks.com featured highlights include: Bausch Health, Endava, DaVita, Perspecta and Athene Holding

2018-10-09 zacks
Chicago, IL – October 9, 2018 - Stocks in this week’s article are Bausch Health Companies Inc. (BHC - Free Report) , Endava plc (DAVA - Free Report) , DaVita Inc. (DVA - Free Report) , Perspecta Inc. (PRSP - Free Report) and Athene Holding Ltd. (ATH - Free Report) .
GFN GFNCP VTNR ATH LBTY FNLC CLH LBTYK LILAB FBLV FBP DAVA LBTYB LBTYA GFNSL BRK.A PRSP LILAK FBPRM FBNC FBPRL GFDV FBPRO FBPRN FBPRP LILA BHS

18
Zacks.com featured highlights include: Range Resources, lululemon athletica, North American, ChannelAdvisor and Southwest Gas

2018-10-09 zacks
Chicago, IL – October 9, 2018 - Stocks in this week’s article are Range Resources Corporation (RRC - Free Report) , lululemon athletica inc. (LULU - Free Report) , North American Construction Group Ltd. (NOA - Free Report) , ChannelAdvisor Corporation (ECOM - Free Report) and Southwest Gas Holdings, Inc. (SWX - Free Report) .
SWX GFN GFNCP VTNR LBTY FNLC RRL CLH LBTYK LILAB FBLV LULU FBP LBTYB LBTYA RRS RGRLF GFNSL RRC BRK.A ECOM RGRYY LILAK FBPRM FBNC FBPRL GFDV FBPRO FBPRN FBPRP LILA

4
The Zacks Analyst Blog Highlights: Korn/Ferry, General Finance, Vertex Energy, First Bancorp and Berkshire Hathaway

2018-10-09 zacks - 1
Chicago, IL –October 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Korn/Ferry International (KFY - Free Report) , General Finance Corp. (GFN - Free Report) , Vertex Energy, Inc. (VTNR - Free Report) , First Bancorp (FBNC - Free Report) and Berkshire Hathaway Inc.
FBP GFN GFNCP VTNR FNLC LXFR JRVR KFY GFNSL BRK.A FRBA BSTC FBLV FBNC FBPRM FBPRL ADM GFDV UTHR FBPRO FBPRN UIHC FBPRP

4
The Zacks Analyst Blog Highlights: Steelcase, Clean Harbors, General Finance, CPI Card and Conduent

2018-10-09 zacks
Chicago, IL –October 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Steelcase Inc. (SCS - Free Report) , Clean Harbors, Inc. (CLH - Free Report) , General Finance Corp. (GFN - Free Report) , CPI Card Group Inc.
GFN GFNCP PMTS LXFR CLH JRVR GFNSL SCS CNDT BSTC ADM UTHR GFDV PNT UIHC

 
The Motor & General Finance Limited - Shareholders meeting

2018-10-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GFN GFNCP GFDV GFNSL

3
American Labor Market Hale and Hearty: Top 5 Winners

2018-10-08 zacks
The labor market is in excellent shape, with unemployment hitting the lowest level in September since the Vietnam War. Though jobs addition slowed down nominally last month due to Hurricane Florence, it is expected to pick up for sure. Let us, thus, take a look at stocks that made the most of the robust labor market.
FBP GFN GFNCP VTNR FNLC KFY GFNSL BRK.A FRBA FBLV FBNC FBPRM FBPRL GFDV FBPRO FBPRN FBPRP

 
5 Stocks to Gain From 49-Year Low Unemployment Rate

2018-10-08 zacks
The jobless rate dipped two-tenths of a percentage point to 3.7% in September and touched its lowest level in nearly 50 years. Further, the initial job counts for August and July were revised substantially upward.
SCS GFN GFNCP MATX ZBRA GFDV GFNSL

4
Unemployment Falls to 49-Year Low: 5 Business Services Picks

2018-10-08 zacks
In September, the unemployment rate declined to its lowest level in nearly 49 years. However, job additions came in significantly below expectations, even though the broader employment picture remained robust. Further, even though September’s numbers missed targets, the figures for July and August were revised upward. Also, the labor force participation rate remained unchanged.
SCS CNDT GFN HD GFNCP PMTS GFDV PNT CLH GFNSL

14
Zacks.com highlights: MCBC Holdings, Newpark Resources, Cigna, Weight Watchers International and Ligand Pharmaceuticals

2018-10-05 zacks - 1
Chicago, IL – October 5, 2018 - Stocks in this week’s article include: MCBC Holdings, Inc. (MCFT - Free Report) , Newpark Resources, Inc. (NR - Free Report) , Cigna Corp. (CI), Weight Watchers International, Inc. (WTW - Free Report) and Ligand Pharmaceuticals (LGND - Free Report) .
GFN GFNCP WCG LGNDZ EW COF-D COF-C COF-F LGNYZ CI HUBG COF-P MCFT WTW COF ISRG GFNSL YY AAWW AIMC LGNZZ LGND NR LGNXZ GFDV HUBOF

9
Zacks Value Investor Highlights: JP Morgan Chase, Wells Fargo, Bank OZK, First Republic Bank and Comerica

2018-10-05 zacks
Chicago, IL – October 5, 2018 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: (https://www.zacks.com/stock/news/326287/bank-stocks-are-cheap-should-you-be-buying)
GFN GFNCP EW HUBG COF-P CMA ISRG OZK AAWW GFDV HUBOF WFCNP FRC WCG COF-D COF-C COF-F WFC COF YY GFNSL AIMC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 369822101